NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) D
Post# of 112
(Total Views: 256)
Posted On: 01/11/2023 3:00:57 PM
NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Dedicated to New Era of Precision Medicine
Aditxt (NASDAQ: ADTX), a biotech innovation company, is developing and commercializing technologies with a focus on monitoring and modulating, mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. “In late October 2022, Aditxt announced the creation of its Adimune(TM) program. At the same time, Aditxt announced that Adimune initiated the GMP manufacturing of drug candidate ADI(TM)-100 for purposes of initiating human trials. The trial will be performed in autoimmune diseases, with psoriasis as the first indication to be studied. Adimune’s nucleic acid-based technology, ADI(TM), has shown in preclinical studies the ability to restore/induce immune tolerance in an antigen-specific way without impairing the immune response to fight infections and cancer. According to Amro Albanna, co-founder, chairman and CEO of Aditxt, the company’s vision is dedicated to a new era of precision medicine through individual immune monitoring and modulation,” reads a recent article. “We are laser-focused on advancing each of our innovation programs toward commercialization. Adimune’s initiation of ADI-100 manufacturing is measurable progress of Adimune toward our 2023 strategic goals,” Albanna is quoted saying.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Aditxt (NASDAQ: ADTX), a biotech innovation company, is developing and commercializing technologies with a focus on monitoring and modulating, mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. “In late October 2022, Aditxt announced the creation of its Adimune(TM) program. At the same time, Aditxt announced that Adimune initiated the GMP manufacturing of drug candidate ADI(TM)-100 for purposes of initiating human trials. The trial will be performed in autoimmune diseases, with psoriasis as the first indication to be studied. Adimune’s nucleic acid-based technology, ADI(TM), has shown in preclinical studies the ability to restore/induce immune tolerance in an antigen-specific way without impairing the immune response to fight infections and cancer. According to Amro Albanna, co-founder, chairman and CEO of Aditxt, the company’s vision is dedicated to a new era of precision medicine through individual immune monitoring and modulation,” reads a recent article. “We are laser-focused on advancing each of our innovation programs toward commercialization. Adimune’s initiation of ADI-100 manufacturing is measurable progress of Adimune toward our 2023 strategic goals,” Albanna is quoted saying.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)